MDB Capital Holdings, LLC (MDBH) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture with potential positive catalysts like the HeartBeam FDA approval and promising partnerships, but also highlights significant risks such as macroeconomic uncertainties, execution risks, and distribution challenges. The financial health shows moderate cash burn and strategic investments, yet the unclear guidance on PatentVest's spin-out and dilution concerns for eXoZymes add uncertainty. The Q&A session reveals management's reluctance to provide concrete details, further tempering sentiment. Thus, the overall impact on stock price is expected to be neutral.
Key Financial Performance
Fixed Operating Expenses $10 million for the year, with a cash burn of $5.7 million. However, $4 million of this was invested in clearing operations and PatentVest. Excluding this investment, the effective cash burn was $1.7 million. The reduction in operating expenses post-spinout of clearing platform and PatentVest is expected to bring it down to $6 million annually.
Portfolio Asset Value - eXoZymes Market valuation at year-end was approximately $45 million, but it has since decreased to $30 million. The company is at a critical development point, focusing on scaling manufacturing for synbio products.
Portfolio Asset Value - Paulex MDB owns 7.1 million shares. The IPO pricing is yet to be determined, but it is expected to be a substantial asset. Paulex is initiating clinical trials for a potential game-changing diabetes drug.
Investment in MDB Direct and PatentVest Approximately $4 million annually since the IPO. MDB Direct is operational and has potential for monetization through strategic partnerships or spinouts. PatentVest is positioned as a law firm and is also being prepared for a spinout.
Cash and Current Assets $22.3 million at year-end, including marketable securities, less current liabilities. The delayed completion of the Buda Juice deal into January will provide some benefit in the first quarter.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
AI Integration: MDB has integrated AI into its operations, significantly improving efficiency in due diligence and company preparation for IPOs. This has reduced the time required for these processes by two-thirds, enabling faster scaling.
PatentVest Development: PatentVest has been developed into an ABS IP law firm, allowing MDB to provide higher-quality patents and partner with big law firms. This is expected to create significant value and is planned for a spinout as an independent entity.
Paulex IPO: MDB is preparing Paulex for an IPO later this year, with clinical trials for a diabetes-related drug expected to begin in September.
Clearing Operations: MDB Direct has been developed as a self-clearing platform, a unique asset in the microcap marketplace. MDB is exploring strategic partnerships to monetize this asset and solve distribution challenges.
Operational Efficiency: AI has been implemented to streamline operations, reducing the time for due diligence and company preparation from months to weeks.
Cost Management: Post-spinout of PatentVest and MDB Direct, operating expenses are expected to reduce to $6 million annually, enhancing financial leverage.
Scaling IPOs: MDB aims to scale from launching one company every 18 months to 3-5 companies annually, leveraging AI and operational improvements.
Asset Spinouts: Plans to spin out PatentVest and MDB Direct as independent entities to unlock value and focus on core operations.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Macro and Global Risks: Uncertainty in macroeconomic and global conditions could adversely impact the company's operations and strategic objectives.
Microcap Market Conditions: Difficult conditions in the microcap market, including severe dilution faced by small companies, pose challenges to the company's portfolio and operations.
Execution Risk: Both the company's execution and the execution of its portfolio companies are critical and pose significant risks to achieving strategic goals.
Distribution Gap: The company faces challenges in scaling its distribution capabilities, which is a major concern for its ability to launch and support multiple companies annually.
Clinical and Regulatory Risks: Life science companies in the portfolio face inherent clinical and regulatory risks that could impact their success and valuation.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Scaling IPO Launches: MDB Capital aims to scale from launching one company every 18 months to 3-5 companies annually. This is expected to be achieved through the integration of AI tools to streamline due diligence and preparation processes, reducing the time required from 6-18 months to weeks.
AI Integration: The company is leveraging AI to enhance operational efficiency, particularly in due diligence, patent analysis, and company preparation for IPOs. This is expected to significantly reduce time and labor requirements, enabling faster scaling.
Spinout of MDB Direct and PatentVest: MDB Capital plans to spin out its clearing operations (MDB Direct) and PatentVest as independent entities. MDB Direct is expected to attract strategic partnerships or outright sale, while PatentVest aims to become a public ABS law firm, focusing on patent prosecution and leveraging AI.
Portfolio Companies: MDB Capital is optimistic about its portfolio companies, including eXoZymes and Paulex. eXoZymes is focusing on scaling manufacturing in synthetic biology, while Paulex is preparing for an IPO and clinical trials for a diabetes-related drug later this year.
Financial Efficiency: Post-spinout of MDB Direct and PatentVest, operating expenses are expected to reduce to $6 million annually, enabling the company to launch multiple high-value companies with significant financial leverage.
Market Trends and Distribution: The company is addressing distribution challenges for public venture IPOs by exploring partnerships and leveraging its clearing platform. It anticipates changes in retail investor participation and aims to capitalize on these trends.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you talk about Cue, ClearSign, Beam, and Buda?
A:ClearSign is on a long commercialization journey with unique burner technology relevant for increased natural gas usage. HeartBeam achieved FDA approval for a pocket 12-lead ECG, potentially the first device to detect heart attacks, with significant commercialization challenges. Buda is seen as a leader in the fresh juice market, addressing a global shift towards fresh food, and is profitable. Cue Bio has struggled with management and commercialization but has partnered with Boehringer Ingelheim and ImmunoScape, with promising opportunities in the pipeline.
Q:What are your thoughts on eXoZymes and its dilution prospects?
A:eXoZymes operates with a $10 million OpEx to create significant opportunities in NCT and cannabinoids. The company is capital efficient, outsourcing manufacturing, and leveraging government grants. Dilution is expected to be minimal as the company focuses on commercialization and high-impact platforms with TAMs in the hundreds of billions.
Q:How will the PatentVest spin-out impact shareholders?
A:MDB owns 100% of PatentVest and plans to bring in strategic partners through financing. The spin-out is expected to occur by 2027, with the method and valuation still under consideration. Shareholders will benefit from the spin-out as it becomes an independent division.
Q:What does the deal pipeline look like for the next 12 to 24 months?
A:The deal pipeline is strong, but the main challenge is distribution. MDB aims to broaden its investor base and solve distribution issues to increase the number of deals. The focus is on finding investors for the companies launched.
Q:Would you consider a SaaS model for PatentVest?
A:The SaaS model is seen as being disrupted by AI. PatentVest has reduced patentability analysis time from 45 hours to 1.5 hours using AI, making curated AI solutions less valuable. The future is seen in human-in-the-loop IP development rather than SaaS.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the valuation and method of the PatentVest spin-out, stating that it is still under consideration and dependent on future partnerships and funding.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Capital President
Community Development
Conference today
Development update
Factors press
Full Update
Head Community
Holdings Full
Holdings MDB
Instructions host
Instructions question
Investor Relations
MDB Welcome
President Head
Relations section
Today conference
Update Conference
Welcome MDB
afternoon Investor
answer session
conference answer
heading Risk
moderator statement
presentation Instructions
presentation Today
presentation result
question moderator
release result
replay Capital
result wire
risk heading
section website
session presentation
today Chief
today Instructions
MDBH Transcript
MDB Capital Holdings, LLC (MDBH) Q4 2025 Earnings Call Transcript
Unknown3-31
The earnings call presents a mixed picture with potential positive catalysts like the HeartBeam FDA approval and promising partnerships, but also highlights significant risks such as macroeconomic uncertainties, execution risks, and distribution challenges. The financial health shows moderate cash burn and strategic investments, yet the unclear guidance on PatentVest's spin-out and dilution concerns for eXoZymes add uncertainty. The Q&A session reveals management's reluctance to provide concrete details, further tempering sentiment. Thus, the overall impact on stock price is expected to be neutral.
MDB Capital Holdings, LLC (MDBH) Q3 2025 Earnings Call Transcript
Unknown11-20
The earnings call reveals mixed signals: while there are promising investments like eXoZymes and HeartBeam awaiting FDA approval, the company's financial performance is contingent on future revenue and financing. The Q&A highlights concerns about shareholder dilution and management's vague timelines. Although the potential for high returns exists, the lack of immediate catalysts and uncertainties around approvals and timelines suggest a neutral impact on stock price.
MDB Capital Holdings, LLC Class A common (NASDAQ:MDBH) Q4 2024 Earnings Call Transcript
Unknown4-5
The earnings call presents a mixed picture. Financial performance is strong, with revenue and net income growth, but there are concerns about delays in SEC filings and uncertainties in forward-looking statements. The deconsolidation of Invizyne simplifies financial analysis but raises compliance issues. The Q&A session revealed limited additional insights and some management evasiveness, which may affect investor confidence. Overall, the strong financial metrics are offset by operational uncertainties, leading to a neutral sentiment.
MDB Capital Holdings, LLC (MDBH) Q4 2024 Earnings Call Transcript
Unknown4-3
The earnings call summary reveals several concerns: negative market value, regulatory issues, and cash flow challenges. Despite optimistic future revenue expectations and shareholder return plans, the Q&A section highlights management's vague responses and uncertainty in regulatory environments. The lack of strong positive catalysts and the negative perception of the company's financial health contribute to a negative sentiment, likely resulting in a stock price decline of 2% to 8% over the next two weeks.
MDBH Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
